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Abstract
Purpose—Although racial disparities in health-related quality of life (HRQOL) among women 
with breast cancer (BC) are well documented, less is known about HRQOL changes over time 
among women of different races. Our objective was to assess racial differences in HRQOL during 
active treatment and survivorship phases of BC care.
Methods—We used data from the third phase of the Carolina Breast Cancer Study (CBCS-III). 
CBCS-III enrolled 3,000 women in North Carolina aged 20-74 years diagnosed with BC between 
2008 and 2013. HRQOL assessments occurred 5- and 25-months post-diagnosis, representing 
distinct phases of care. HRQOL measures included the Functional Assessment of Cancer Therapy 
for BC and Functional Assessment of Chronic Illness Therapy for Spiritual Well-Being. Analysis 
of covariance models were employed to assess racial differences in changes in HRQOL.
Results—The cohort included 2,142 Non-Hispanic White (n=1,105) and Black women 
(n=1,037) who completed both HRQOL assessments. During active treatment, Whites reported 
physical and functional scores 2-2.5 points higher than Blacks (p<0.0001). Spiritual HRQOL was 
2.1 points higher for Blacks (p<0.0001). During survivorship, differences persisted. After 
adjusting for demographic, socioeconomic, tumor and treatment characteristics, physical and 
functional HRQOL gaps narrowed, but spiritual HRQOL gaps widened.
Conclusions—Racial differences in physical and functional HRQOL during active treatment 
and survivorship may be largely mediated by socioeconomic factors. However, our results suggest 
that among Black women, spiritual HRQOL is well supported throughout the BC care continuum. 
Contact Information: Laura C. Pinheiro, MPH, Department of Health Policy and Management, Gillings School of Global Public 
Health, University of North Carolina, 1101 McGavran-Greenberg Hall, CB#7411, Chapel Hill, NC 27599-7411, 
lpinheir@live.unc.edu. 
Compliance with Ethical Standards:
Conflict of Interest: Authors Dr. Samuel and Dr. Wheeler have received a research grant from Pfizer for another unrelated study. All 
other authors (Ms. Pinheiro, Dr. Reeder-Hayes, Dr. Olshan and Dr. Reeve) declare that they have no conflicts of interest to disclose.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional 
and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
HHS Public Access
Author manuscript
Breast Cancer Res Treat. Author manuscript; available in PMC 2017 October 01.
Published in final edited form as:
Breast Cancer Res Treat. 2016 October ; 159(3): 535–543. doi:10.1007/s10549-016-3965-y.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
These results inform opportunities for improving the quality and equity of supportive services for 
women with BC.
Introduction
Over 3 million women in the United States (U.S) are currently living with breast cancer 
(BC) or have a history of BC [1]. Given that 5- and 10-year BC survival rates are 90% and 
80%, respectively, most women diagnosed with BC become long-term survivors [2]. As the 
number of women surviving BC grows, monitoring and characterizing changes in health-
related quality of life (HRQOL), as well as identifying women at high-risk for long-term 
HRQOL deterioration during survivorship, is critical to ensuring patient-centered care across 
the BC care continuum.
Thirty percent of women experience poor psychosocial and physical HRQOL before, during, 
and after treatments [3,4]. Women with BC report greater levels of treatment-related 
symptoms compared to similarly aged healthy women [5-7]. Studies have shown BC is a 
risk factor for poor mental health, and rates of depression are twice as high among adults 
with cancer than those without cancer [7,8].
BC risk and burden varies systemically between Black and White women [9]. Although BC 
incidence rates do not differ significantly between Black and Whites, Blacks are more likely 
to die from BC [2]. Black women are more likely to be diagnosed at younger ages with more 
aggressive tumors [10]. As Blacks are over-represented in lower socioeconomic groups, they 
may be more likely to experience diagnosis and treatment delays associated with worse 
survival [11] [12].
Racial gaps in HRQOL are well-documented in BC, but differences are not uniform across 
ages or HRQOL domains [3,13-17]. Specifically, compared with their White counterparts, 
Black women with BC report worse physical and functional HRQOL [17,18]. However, this 
may not be the case at different phases of BC care. A retrospective Medicare study found 
that while racial disparities in HRQOL were prevalent before cancer diagnosis, gaps in 
certain domains narrowed following exposure to the cancer care system [15]. Once Black 
women are diagnosed with BC and engage with the health care system, Black-White 
differences may narrow because previously unaddressed needs are met, which positively 
impacts HRQOL [15].
To our knowledge, no study has assessed racial disparities in changes in individual HRQOL 
domains over time in a large, multi-payer, population-based cohort. Our objective was to 
determine whether or not HRQOL varied between White and Black women during active 
treatment, survivorship, and in changes between these two time points. To do this, racial 
differences in six HRQOL domains (i.e., physical, social, emotional, functional, and spiritual 
well-being, and BC-specific concerns) were examined between 5- and 25-months after 
diagnosis among Black and White women with BC in North Carolina.
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Methods
Data
Data for this study came from the third phase of the Carolina Breast Cancer Study (CBCS-
III). CBCS-III enrolled 3,000 women diagnosed with incident, invasive, pathologically 
confirmed BC between 2008 and 2013. Participants spanned 44 counties in North Carolina 
and were identified using rapid case ascertainment [12]. To ensure representation of young 
and Black women, eligible participants were sampled from four strata (sampling fractions in 
parentheses): Blacks under 50 years (100%), Blacks 50 years and older (60%), Whites under 
50 years (40%), and Whites 50 years and older (15%) [12]. As such, 50% of CBCS-III 
consists of Black women, of whom approximately half are under 50. CBCS-III includes 
women residing in rural and urban settings, with private and/or public insurance (and 
uninsured), and those of varying income levels [12]. In-person surveys were administered to 
women within 9-months of diagnosis, and at a median of 5.2 months post-diagnosis 
(referred to as the “5-month survey” and ranging from 1.8-8.9 months) [12]. Surveys 
collected data on demographics, socioeconomics and HRQOL [12,19]. Twenty-five months 
post-diagnosis women completed a follow-up mail-in survey, which included HRQOL 
questionnaires. Participants completed informed consent, including permission for 
researchers to abstract medical records [12,19]. This study was approved by the Institutional 
Review Board at the University of North Carolina at Chapel Hill.
Participants
As the study was interested in changes in HRQOL between active treatment and 
survivorship (in terms of diagnosis and primary treatment), the cohort was restricted to 
women who completed both 5-and 25-month surveys. Furthermore, as the focus of this 
study was in Black-White differences in HRQOL, only Non-Hispanic Black and White 
women were included. Of the 2,998 women who completed a 5-month survey, 2,561 (85%) 
completed a 25-month survey. Additionally, 97 (4%) women were excluded because they 
identified as “other race” or Hispanic. Women with distant stage BC represented less than 
3% of the cohort and were excluded to ensure tumor and treatment homogeneity. The final 
cohort included 2,142 women.
Outcomes
HRQOL instruments included the Functional Assessment of Cancer Therapy for BC (FACT-
B) and the Functional Assessment of Chronic Illness Therapy for Spiritual Well-Being 
(FACIT-SP). The FACT-B includes 5 domains: Physical Well-Being, Social Well-Being, 
Emotional Well-Being, Functional Well-Being, and BC-specific Concerns [20]. The FACT-B 
has been validated and shown to be responsive among women with BC [20]. Minimally 
important differences (MID) or smallest differences in HRQOL perceived as clinically 
meaningful are 2-points per domain [21].
The FACIT-SP is a validated chronic disease specific and includes the Spiritual Well-Being 
domain [20]. The FACIT-SP is the most commonly used instrument to measure spiritual 
well-being in cancer [22]. As with the FACT-B, higher scores indicate better HRQOL [20] 
[22].
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Independent Variable
Self-reported race (Non-Hispanic Black or White).
Covariates
Demographic and lifestyle characteristics included age at diagnosis, smoking status, body 
mass index, and comorbid conditions (e.g., diabetes, chronic obstructive pulmonary disease, 
obesity, hypertension, and heart disease). Socioeconomics included marital status, education, 
family income, urban/rural residence, and insurance status at 5-months. Given a high degree 
of collinearity between socioeconomic factors (r>0.80), only education and insurance status 
were included in our models. Treatment covariates included surgery, radiation, 
chemotherapy, and Herceptin. Although we examined racial differences by tumor stage, size, 
grade, nodal status, and hormone receptor (HR) status, due to collinearity (r>0.80), we only 
controlled for tumor stage and HR status.
Statistical analysis
We compared characteristics between Black and White women using t-tests for continuous 
covariates and chi-square tests for categorical variables. We tested differences in unadjusted 
mean HRQOL scores for FACT-B and FACIT-SP domains between Black and White 
women. We also compared physical, functional, social and emotional well-being domains 
[23]. Changes in HRQOL domains between 5- and 25-months were calculated as 5-month 
scores subtracted from 25-month scores. Positive changes show improvements and negative 
changes denote decrements.
Analysis of covariance (ANCOVA) models were used to examine predictors of HRQOL at 
25-months, adjusting for 5-month scores, demographics, comorbidities, socioeconomics, 
treatment, and tumor characteristics. Each model's outcome was the 25-month HRQOL 
score. We ran one model per domain to isolate domain-specific predictors that may be 
masked by overall HRQOL score. Given a sample size of 2,142 women and significance 
level of 5%, we were powered at nearly 100% to detect minimally important differences 
(MIDs) for each domain. Analyses were performed in SAS 9.3 with two-sided statistical 
tests and a significance level of 5% for all analyses.
Assessing Racial Disparities
We explored three approaches to assessing racial disparities to better understand if racial 
gaps in HRQOL existed and to identify potential mediators of HRQOL disparities. 
ANCOVA models controlling for race, treatment and tumor characteristics, but not 
socioeconomic factors were estimated. Differences in adjusted Least Square Means (LSMs) 
between Black and White women were tested for each domain. This was the study's primary 
approach and is consistent with the Institute of Medicine's (IOM) operationalization of racial 
disparities in health care, which conceptualizes race as a social construct linked to a range of 
mediating factors, including socioeconomic status [24]. The IOM considers a disparity as 
the difference in quality of care between two racial groups that cannot be explained by 
clinical differences, health status or patient preferences [25]. The motivation behind this 
approach is that minority groups are overrepresented in low socioeconomic groups; thus, 
including both race and socioeconomics in a model may underestimate racial differences 
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[24]. The following two approaches were implemented as sensitivity analyses to explore the 
extent to which racial differences were mediated by measurable socioeconomic factors.
ANCOVA models controlling for race and socioeconomic factors (and tumor and treatment 
characteristics) were estimated. Differences in adjusted LSMs between Blacks and Whites 
were tested. This approach is the residual direct effect (RDE) of race on health care, because 
it controls for all measurable mediators of the relationship between race and the outcome, 
thereby resulting in a “race” parameter estimate reflecting the unmediated effect of race on 
HRQOL [25] [26].
Models testing interaction terms between race and socioeconomic factors were estimated. 
This final approach treated race and socioeconomic status as distinct constructs which have 
independent and interactive effects on HRQOL [24]. That is, socioeconomic status is on the 
causal pathway between race and HRQOL and may moderate associations [27].
As additional sensitivity analyses, we ran race-stratified models to determine if race 
modified relationships between individual characteristics and HRQOL. An age-stratified 
model was also run to evaluate if disparities existed among women below or above age 40, 
which is the age at which women begin mammography screening. Finally, models stratifying 
women by menopausal status were estimated to determine if relationships between race and 
HRQOL varied.
Results
Participant characteristics
Table 1 presents race-stratified characteristics of the cohort. Age at diagnosis, surgery type, 
receipt of Herceptin, and prevalence of COPD and heart disease did not differ significantly 
between groups. Compared to Whites, Blacks were less likely to be married, have public 
insurance, and less education. Diabetes, obesity and hypertension were twice as common 
among Blacks. Blacks were more likely than Whites to be diagnosed with later stage BC and 
receive aggressive treatments such as chemotherapy and radiation.
Unadjusted HRQOL
During active treatment (5-month survey), mean physical well-being scores were 1.2-3.7 
points below U.S norm scores (Table 2) [23]. White women reported physical and functional 
well-being scores 2.5 and 1.9 points higher, respectively, than Blacks (p<0.0001). Blacks 
reported spiritual well-being scores 2.1 points higher than Whites at 5-months (p<0.0001).
During survivorship (25-month survey), Whites reported HRQOL scores above U.S norms 
across physical, social, emotional and functional well-being domains (Table 2, Figures 1-4) 
[23]. Blacks, however, reported physical well-being scores 1.2 points below U.S norms and 
2.3 points below their White BC counterparts (p<0.0001). Whites reported functional well-
being scores 2.4 points higher on average than Blacks (p<0.0001), exceeding MID 
thresholds. Black women reported spiritual well-being scores 2-points higher than Whites 
(p<0.0001).
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As women entered survivorship, MIDs of 2.3-2.5 points (improvements over time) were 
seen in physical well-being for Whites and Blacks. We did not observe meaningful changes 
for other domains (Table 2). On average, social well-being declined 1-point from 5- to 25-
months for both groups, but was 1.7-3.0 points above U.S norms (Figure 2). From active 
treatment to survivorship, spiritual well-being declined 1-point for both groups while 
emotional well-being remained unchanged. On average, Black-White differences in HRQOL 
changes from 5- to 25-months ranged from 0.1-0.8 points. Differences between Blacks and 
White in functional well-being and BC-specific concerns changes from 5- to 25- months 
were statistically significant, but did not exceed MID thresholds.
Adjusted HRQOL
In models adjusting for characteristics in Table 1, older age was significantly associated with 
better HRQOL at 25-months across all domains (Table 3). Being a smoker was associated 
with 1.2-1.9-point decreases in HRQOL across domains except for social well-being. Higher 
education was associated with the largest increase in physical and functional HRQOL. 
Obesity was significantly associated with decreases in BC-specific concerns.
IOM
We observed statistically significant racial differences in physical, emotional, functional and 
spiritual well-being (Figure 5) during survivorship. Specifically, Whites had physical and 
functional well-being scores 0.5 (p<0.05) and 1.0 (p<0.0001) points higher, respectively, 
than Blacks. However, Blacks had emotional and spiritual well-being scores 0.5 (p<0.05) 
and 0.8 (p<0.01) points, respectively, higher than Whites. Differences were statistically 
significant, but none exceeded 2-point MID thresholds.
RDE
Once socioeconomics were added to adjusted models, emotional, functional, and spiritual 
well-being domains remained significantly different between Black and White women 
(Figure 5) during survivorship. Black race was significantly associated with a 0.5-point 
(p<0.01) increase in emotional well-being and a 1.2-point (p<0.01) increase in spiritual 
well-being, while White race was associated with a 0.5-point (p<0.05) increase in functional 
HRQOL. Although differences were statistically significant, none exceeded 2-point MID 
thresholds.
Race and Socioeconomic Interactions
Interaction terms between race and socioeconomic factors were not statistically significant at 
the 0.05 level.
Sensitivity Analyses
In race-stratified models, patient and treatment characteristics had similar associations with 
HRQOL in terms of estimates’ direction, magnitude and significance for Blacks and Whites 
(results not shown). One notable difference was that among Black women, receipt of 
Herceptin was significantly associated with 0.8-1.2 point lower physical, emotional, 
functional and BC-specific concerns scores (p<0.01), but this association was not seen 
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among Whites. White-Black Differences in HRQOL by age or menopausal status were not 
observed.
Discussion
Domain-specific HRQOL patterns were examined to assess if Black and White women with 
BC are equally susceptible to poor HRQOL during active treatment and survivorship. Using 
the RDE approach, we found statistically significant, but not clinically meaningful Black-
White differences in emotional and spiritual well-being at 25-months. Implementing the 
IOM approach, we again found small, but significant differences in physical, functional, 
emotional and spiritual well-being domains during survivorship. These findings are similar 
to other BC survivor studies that found racial differences in HRQOL following treatment 
were small and not clinically meaningful [28]. Previous work attributed racial differences in 
HRQOL to BC stage, treatments, comorbidities, and socioeconomics related to health care 
access [29].
Racial differences in physical and functional HRQOL appear to be mediated by 
socioeconomics. Race coefficients for physical and functional well-being domains 
attenuated by 50% once socioeconomics were controlled for, whereas emotional and social 
well-being coefficients remained unchanged. Gaps in spiritual well-being actually widened 
once socioeconomics were added to the model. Worse physical and functional HRQOL may 
be related to racial differences in access (e.g., financial barriers) to cancer care, which often 
emphasize management of physical and functional effects of cancer and its treatment [30]. 
Thus, racial differences in access to care are more likely to impact physical and functional 
well-being. Furthermore, physical and functional HRQOL may be impacted by comorbid 
conditions such as obesity, diabetes and hypertension, all of which were more prevalent in 
Black women in our study. A systematic review of BC survivors concluded that, in general, 
Black women report worse physical and functional well-being than their White counterparts, 
however, once demographic, socioeconomic and medical characteristics were adjusted for, 
physical and functional well-being differences between Black and White women attenuated, 
suggesting differences may be largely mediated by demographic and socioeconomic factors 
[31]. Socioeconomic-related barriers to physical and functional well-being must be 
addressed to help narrow gaps in these domains. Potential ways to improve physical and 
functional HRQOL could be to help manage other comorbidities and promote greater 
physical activity. Black women with BC tend to report lower levels of physical activity, 
which has been associated with poorer physical well-being and overall HRQOL [3,32]. 
Studies have also confirmed that although BC survivors report less physical activity 
compared to the general population, Whites with BC have higher levels of physical activity 
compared to Blacks, which may facilitated by physical well-being and vitality [17,18,32].
Our findings are consistent with previous work concluding that women with BC report 
greater levels of social support compared to healthy women their age [33]. Increased social 
support among women with BC has been associated with better adjustment following 
primary BC treatments [30,34]. As such, it is not surprising that women in our study 
reported social well-being scores well above U.S norms during active treatment. Black 
women were less likely to be married, suggesting that their social support may have come 
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from sources other than partners (i.e., community, religious organizations) [30]. Previous 
studies also suggest Blacks experience positive growth following BC diagnosis and 
treatment, which may support social and emotional well-being [33,35].
Black women consistently report the importance of spirituality in coping with BC 
[18,36,37]. Spirituality has been described as a source of hope and comfort for Black women 
struggling with the psychosocial burden of BC diagnosis and treatment [35]. In fact, 
clinicians have been recommended to promote spirituality as a coping mechanism among 
Black women with BC, as it may mitigate effects of BC on psychosocial health [31] [35]. 
This is consistent with our findings that Blacks reported significantly higher levels of 
emotional and spiritual well-being than Whites, even after adjusting for patient 
characteristics.
Emotional and spiritual well-being were the only HRQOL domains not attenuated by 
socioeconomic factors. Racial differences in spiritual well-being actually widened after 
adjusting for socioeconomics. At first, it seems this suggests emotional and spiritual well-
being domains may not be impacted by socioecological burden Black women more often 
endure [18]. Financial stressors, urban residence, job insecurity, and balancing multiple 
responsibilities (e.g., house, parental, job) make dealing with BC more difficult for Blacks 
[17,18,31]. Following diagnosis, Black women struggle with these challenges, exacerbating 
physical and functional well-being, which often decline following BC treatment [17,18]. 
This is in line with our observations that physical and functional HRQOL were lower among 
Blacks during active treatment. Emotional and spiritual well-being domains, however, 
appear more resistant to life stressors affecting other domains due to increased spirituality 
and community support. Another possibility is that BC and socioeconomic factors actually 
impact emotional and spiritual well-being, but in a way that reinforces these domains. The 
Superwoman role, a theory stating Black women feel they must exude strength, suppress 
emotions, and demonstrate perseverance when faced with adversity, may partially explain 
this [38]. If Black women do not allow themselves to acknowledge weakness or stress 
related to BC, self-reported emotional and spiritual well-being may not appear to suffer [38].
Limitations
First, we only included Non-Hispanic Black and White women in North Carolina, limiting 
generalizability to women outside of the state and of other racial groups. As most women 
have initiated primary BC treatments by 5-months, there is no pre-treatment HRQOL 
measure. However, BC treatments (from medical records) were adjusted for in analyses. We 
were unable to control for unmeasured confounders such as patient preferences, culture, 
economic, political, and legal factors that may impact HRQOL.[27] As such, even in 
conservative models, race coefficients encompassed unmeasurable factors such as 
institutional racism, different care seeking behavior and access to health care networks that 
are not determined by insurance status, education and income, introducing potential bias.
Conclusion
The richness of CBCS-III made it an ideal platform to understand racial disparities in 
HRQOL among women with BC in North Carolina. Statistically significant racial 
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differences in HRQOL changes (from active treatment to survivorship) were identified, but 
differences were not considered clinically meaningful. Results suggest socioeconomic 
factors may considerably mediate racial gaps in physical and functional HRQOL between 
White and Black women with BC. Supportive services should consider domain-specific 
findings to provide targeted HRQOL management across socio-demographic groups of 
women with BC.
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Figure 1. 
HRQOL at 5- and 25-months by race with dotted line representing U.S norms
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Figure 2. 
HRQOL at 5- and 25-months by race with dotted line representing U.S norms
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Figure 3. 
HRQOL at 5- and 25-months by race with dotted line representing U.S norms
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Figure 4. 
HRQOL at 5- and 25-months by race with dotted line representing U.S norms
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Figure 5. 
Adjusted Least Square Mean Differences in 25-Month Scores by HRQOL Domain
Note: Blue dots represent adjusted LSM differences. Grey bars represent 95% confidence 
intervals. Differences calculated as White scores subtracted from Black scores. Negative 
differences indicate White women have higher HRQOL than Black women.
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Table 1
Cohort Characteristics by Race
Whites
N=1,105
Blacks
N=1,037
P-value
Demographics
Age at diagnosis 0.1327
    <35 39 4% 40 4%
    35-50 482 44% 440 42%
    50-64 363 33% 382 37%
    65+ 221 20% 175 17%
Smoking status <0.0001***
    Never 593 54% 607 59%
    Former 346 31% 231 22%
    Current 166 15% 199 19%
Socioeconomics
Married 802 73% 441 43% <0.0001***
Education <0.0001***
    <High School 47 4% 119 11%
    Completed High School 514 47% 594 57%
    College+ 544 49% 324 31%
Insurance status <0.0001***
    None 30 3% 78 8%
    Private 917 83% 618 60%
    Public 158 14% 341 33%
Comorbidities
Diabetes 91 8% 231 22% <0.0001***
COPD 29 3% 24 2% 0.6443
Heart Disease 51 5% 55 5% 0.4629
Obesity 100 9% 190 18% <0.0001***
Hypertension 350 32% 619 60% <0.0001***
Treatments
Surgery 0.2337
    Not specified 11 1% 6 <1%
    Lumpectomy 709 63% 696 66%
    Mastectomy 385 34% 335 32%
Chemotherapy 627 57% 709 68% <0.0001***
Radiation 785 71% 785 76% 0.0149*
Herceptin 143 13% 165 16% 0.0502
Tumor characteristics
Stage <0.0001***
    I 570 52% 416 40%
    II 416 38% 466 45%
    III 119 11% 155 15%
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Whites
N=1,105
Blacks
N=1,037
P-value
Hormone Receptor Status <0.0001***
    Positive/Borderline 909 81% 690 65%
    Negative 196 18% 347 33%
p<0.05 *, p<0.01 **, p<0.0001*
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Table 2
Unadjusted HRQOL Scores by Race and U.S Norms [23]
5-Month Scores 25-Month Scores 5 to 25-month Changes
U.S Norms White Black White Black White Black
Physical 22.1 (5.4) 20.9 (6.0) 18.4 (6.8) 23.2 (5.3) 20.9 (6.3) 2.3 2.5
Social 19.8 (6.8) 23.7 (4.5) 22.6 (5.1) 22.8 (5.3) 21.5 (6.2) −0.9 −1.1
Emotional 19.4 (5.1) 19.4 (3.7) 19.3 (4.5) 19.5 (3.9) 19.5 (4.6) 0.1 0.2
Functional 18.3(6.9) 20.1 (5.8) 18.2 (6.7) 21.8 (5.6) 19.4 (7.0) 1.7 1.2
BC-Specific N/A 23.9 (6.1) 23.6 (6.9) 25.0 (6.3) 23.9 (7.5) 1.1 0.3
Spiritual N/A 39.3 (7.9) 41.4 (7.1) 38.5 (8.7) 40.5 (8.1) −0.8 −0.9
Means (standard deviations). Change was calculated as 5-month scores subtracted from 25-month scores.
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Table 3
Analysis of Covariance Models By HRQOL Domain
25-Month HRQOL
Physical Social Emotional Functional BC-Specific Spiritual
5-Month HRQOL 0.46*** 0.68*** 0.54**** 0.52*** 0.58*** 0.68***
Demographics
Black race (ref=white) −0.17 −0.18 0.54** −0.52* 0.04 1.12**
Age at diagnosis 0.04** 0.03* 0.04*** 0.03* 0.06*** 0.04**
Smoking status (ref=never)
    Former 0.08 −0.27 −0.02 −0.21 −0.31 0.31
    Current −1.34** −0.77* −1.32*** −1.84*** −2.03*** −2.25***
Socioeconomics
Marital status (ref=not married) −0.08 −0.31 0.12 0.24 0.02 0.51
Education level (ref=<HS)
    HS & Post HS 0.76 0.85* 0.56 1.75*** 0.39 0.36
    College+ 1.53** 0.77 0.63 1.95*** 0.57 0.16
Insurance status (ref=private)
    Public −1.55*** 0.01 −0.43* −1.65*** −1.35*** −0.69
    Uninsured −1.72** −0.25 −0.01 −2.02*** −2.14*** −0.25
Comorbid Conditions
Diabetes (ref=no) −0.34 −0.48 −0.23 −0.33 0.52 0.34
COPD (ref=no) −0.93 −0.59 −0.34 −1.45* −0.91 −0.01
Heart Disease (ref=no) −1.04* −0.29 −0.88* −1.22* −0.51 −1.44*
Obesity (ref=no) −0.90*** −0.05 −0.33* −0.66** −1.03*** −0.33
Hypertension (ref=no) −0.11 −0.24 −0.25 −0.21 −0.25 −0.34
Treatments
Surgery (ref=lumpectomy)
    Mastectomy −0.29 −0.11 −0.07 −0.01 −0.56 −0.15
    Not specified 0.36 0.15 1.41 0.65 −0.57 1.89
Chemotherapy (ref=none) 0.24 −0.13 0.03 0.65* 0.52 −0.08
Radiation (ref=none) 0.03 −0.03 −0.02 0.18 0.04 −0.12
Herceptin (ref=none) −0.43 −0.11 −0.35 −0.51 −0.51 −0.35
Tumor characteristics
Stage (ref=Stage I)
    II −0.36 −0.23 −0.28 −0.31 −0.94** −0.13
    III −0.15 0.04 −0.18 −0.15 −1.09* −0.11
HR negative (ref=positive) 0.29 −0.31 0.21 0.27 −0.27 0.18
p<0.05 *, p<0.01 **, p<0.0001* 25-month HRQOL scores are adjusted for HRQOL at 5-months.
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